{"id":4440,"date":"2019-01-23T00:00:00","date_gmt":"2019-01-23T00:00:00","guid":{"rendered":"https:\/\/biovegen.org\/?p=4440"},"modified":"2020-05-06T20:27:29","modified_gmt":"2020-05-06T20:27:29","slug":"cuestionario-sobre-la-normativa-europea-en-materia-de-edicion-genetica","status":"publish","type":"post","link":"https:\/\/biovegen.org\/en\/noticias\/cuestionario-sobre-la-normativa-europea-en-materia-de-edicion-genetica\/","title":{"rendered":"Questionnaire on European Regulations on Gene Editing"},"content":{"rendered":"<p>On July 25, the Court of Justice of the European Union (CJEU) ruled that organisms obtained by mutagenesis (through genetic editing techniques such as CRISPR, among others) constitute Genetically Modified Organisms (GMO) and would be subject to the obligations established in Directive 2001\/18\/EC on GMOs.<\/p>\n\n\n\n<p>The ruling may represent a regression* for genomic editing techniques such as CRISPR and therefore, from BIOVEGEN, and within the framework of the different actions that we have undertaken from the Platform in relation to this matter, we ask for your collaboration in the following questionnaire, developed by ASEBIO in collaboration with the Ministry of Agriculture, Fisheries and Food (MAPA) in order to gather the main concerns of companies in the sector regarding the change in regulations, given the socio-economic impact that this entails for biotechnology companies in the region. health, industrial and agri-food sectors, and how this may affect future developments within these fields.<\/p>\n\n\n\n<p>Your participation in this brief survey is of utmost importance to gather the opinion of the biotechnology business community and convey these concerns to the relevant Spanish authorities that are evaluating the impact of the CJEU ruling.<\/p>\n\n\n\n<div class=\"wp-block-buttons aligncenter is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link\" href=\"https:\/\/es.surveymonkey.com\/r\/asebio-mapa\" target=\"_blank\" rel=\"noreferrer noopener\">TAKE SURVEY<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><em><span class=\"has-inline-color has-vivid-red-color\"><strong>Deadline: <\/strong>January 23, 2019.<\/span><\/em><\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><em>* The GMO Directive that products produced from these techniques will face involves very long and expensive regulatory processes. The CJEU ruling that considers organisms developed through genome editing analogous to GMOs eliminates financial incentives for companies to investigate the process for use in the European Union, in addition to the possible loss of foreign investors or exile of this type of entities to more favorable regulatory environments.<\/em><\/p><\/blockquote>","protected":false},"excerpt":{"rendered":"<p>El pasado 25 de julio el Tribunal de Justicia de la Uni\u00f3n Europea (TJUE) dictamin\u00f3 que los organismos obtenidos por mutag\u00e9nesis (mediante t\u00e9cnicas de edici\u00f3n gen\u00e9tica como CRISPR, entre otras) constituyen Organismos Modificados Gen\u00e9ticamente (OMG) y estar\u00edan sujetos a las obligaciones establecidas en la Directiva 2001\/18\/EC sobre OMG. La sentencia puede suponer una regresi\u00f3n* para [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4441,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[22,40,19],"tags":[],"class_list":["post-4440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualidad","category-aportaciones-biovegen","category-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/posts\/4440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/comments?post=4440"}],"version-history":[{"count":0,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/posts\/4440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/media\/4441"}],"wp:attachment":[{"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/media?parent=4440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/categories?post=4440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biovegen.org\/en\/wp-json\/wp\/v2\/tags?post=4440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}